文献速递治疗药物监测与药物基因组学

实体器官移植中他克莫司患者内变异性的多器官视角

Tacrolimus intrapatient variability in solid organ transplantation: A multiorgan perspective.
PubMed 文献 · Pharmacotherapy · 2020-12-24

多数数据来自成人肾移植受者,高IPV与急性排斥、dnDSA形成、移植物丢失和患者死亡相关;针对IPV的干预研究仅限于小型初步研究。

要点

  • 高他克莫司IPV与急性排斥、dnDSA形成、移植物丢失和患者死亡相关。
  • 多数证据来自成人肾移植受者,其他器官移植数据有限。
  • 针对IPV的干预研究仅限于小型初步研究,需前瞻性探索。

核心结论

  • 高他克莫司IPV与实体器官移植受者不良结局相关,包括急性排斥、dnDSA形成、移植物丢失和患者死亡。

主要发现

  • 多数数据来自成人肾移植受者,发现IPV与排斥、dnDSA形成、移植物丢失和患者生存相关。
  • 评估IPV导向干预的研究仅限于小型初步研究。

关键数值与推荐

  • 变异性测量限于标准差、变异系数和治疗范围内时间。

临床怎么用

  • 临床应关注他克莫司谷浓度的患者内变异性,高IPV可能提示不良结局风险。

局限性

  • 纳入研究均为观察性研究,IPV导向干预证据仅限于小型初步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tacrolimus therapy in solid organ transplant (SOT) recipients is challenging due to its narrow therapeutic window and pharmacokinetic variability both between patients and within a single patient. Intrapatient variability (IPV) of tacrolimus trough concentrations has become a novel marker of interest for predicting transplant outcomes. The purpose of this review is to evaluate the association of tacrolimus IPV with graft and patient outcomes and identify interventions to improve IPV in SOT recipients. METHODS: A systematic review of the literature was performed using PubMed and Embase from database inception to September 20, 2020. Studies were eligible only if they evaluated an association between tacrolimus IPV and transplant outcomes. Both pediatric and adult studies were included. Measures of variability were limited to standard deviation, coefficient of variation, and time in therapeutic range. RESULTS: Forty-four studies met the inclusion criteria. Studies were published between 2008 and 2020 and were observational in nature. Majority of data were published in adult kidney transplant recipients and identified an association with rejection, de novo donor specific antibody (dnDSA) formation, graft loss, and patient survival. Evaluation of IPV-directed interventions was limited to small preliminary studies. CONCLUSIONS: High tacrolimus IPV has been associated with poor outcomes including acute rejection, dnDSA formation, graft loss, and patient mortality in SOT recipients. Future research should prospectively explore IPV-directed interventions to improve transplant outcomes.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Schumacher L, Leino AD, Park JM, et al. Tacrolimus intrapatient variability in solid organ transplantation: A multiorgan perspective. Pharmacotherapy. 2020. PMID: 33131078. doi:10.1002/phar.2480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。